Cell phone in hand
A mobile app that provides up-to-date information on drug shortages has been launched by the Food and Drug... More
Dr. Laurence Albiges
ORLANDO – Talk about a paradox: high body mass index is a known risk factor for renal cell carcinoma, but previous... More
Supreme Court justices appear split on ACA tax subsidies
Supreme Court justices appear to differ over whether the Affordable Care Act allows tax subsidies for patients who... More
21-gene recurrence score assay underwent rapid uptake in U.S. breast cancer patients
A genetic assay designed to predict breast cancer metastasis and response to adjuvant chemotherapy has undergone rapid... More
FDA approves nivolumab for treatment of advanced NSCLC
The Food and Drug Administration has expanded approval of the PD-1 inhibitor nivolumab to include treatment of patients... More
Dr. Martin H. Voss
ORLANDO – A combination of a multitarget tyrosine kinase inhibitor (TKI) with an experimental angiogenesis inhibitor... More
Cancer society critical of new chemo payment bundle
A finalized Medicare payment model for chemotherapy is not much of an improvement from its draft version, according to... More
Dr. Matthew Galsky
ORLANDO – Evidence from randomized clinical trials is all over the map, but a new study using statistical models to... More
Most thyroid nodules have favorable prognosis
During 5 years of follow-up, cancer arose in only 0.3% of thyroid nodules that were cytologically and sonographically... More
NRAS mutations predict immunotherapy outcomes in melanoma patients
Patients with advanced melanoma who were treated with immunotherapy responded better if they harbored mutations in the... More
Dr. Jonathan E. Rosenberg
ORLANDO – A combination of intravesical bacillus Calmette-Guerin (BCG) followed by sunitinib produced high complete... More
Dr. Arlene Siefker-Radtke
ORLANDO – Gene expression profiling can identify intrinsic bladder cancer subtypes, predict the clinical response to... More
PATRICE WENDLING
SAN FRANCISCO – Reducing factor XI levels with the experimental antisense oligonucleotide FXI-ASO lowered venous thromboembolism rates after total knee arthroplasty without increasing bleeding in a phase II study. Venous thromboembolism (VTE) rate... More »
 
PATRICE WENDLING
SAN FRANCISCO – Combining anti-CD38 monoclonal antibodies with standard antimyeloma therapies proved highly active without excessive toxicity in newly diagnosed as well as relapsed or refractory multiple myeloma in a pair of phase Ib studies. “T... More »
 

News

For patients with secondary acute myeloid leukemia, induction therapy with cytarabine in combination with amonafide L-malate did not improve complete remission rates over the standard treatment of cytarabine and daunorubicin, investigators reported o... More »
 

FDA & CDC, News

ELIZABETH MECHCATIE
A mobile app that provides up-to-date information on drug shortages has been launched by the Food and Drug Administration, the agency has announced. The mobile application is “specifically designed to speed public access to valuable information ab... More »
 

Quality Improvement, Reimbursement and Management

RICHARD FRANKI
Participation in the Physician Quality Reporting System (PQRS) varies considerably by specialty, according to an new analysis of 2012 data using primary care physicians as the base, the Centers for Medicare & Medicaid Services reported. Emer... More »
 

Reimbursement and Management

GREGORY TWACHTMAN
A finalized Medicare payment model for chemotherapy is not much of an improvement from its draft version, according to the American Society of Clinical Oncology. The Oncology Care Model developed in the Center for Medicare and Medicaid Innovation is... More »
 
David Henry, MD, FACP
Last month, the American Society of Clinical Oncology (ASCO) designated the transformation of treatment for chronic lymphocytic leukemia (CLL) as the cancer Advance of Year.1 The recognition came after the US Food and Drug Administration approved 4 d... More »
 

Commentaries

S.Y. TAN, M.D., J.D.
Question: C, age 17 years, was diagnosed with Hodgkin’s lymphoma. According to her oncologists, chemotherapy would offer an 80% chance of cure, whereas death within 2 years was almost a certainty without treatment. C refused treatment, a decision s... More »
 
Danielle M Crookes et al
Background Clinical trials are valuable in advancing cancer care through the investigation of ways in which to better prevent, detect and diagnose, and/or treat cancer. Recruitment of adults into clinical trials has historically been low. Objective ... More »
 
Iris Kusters et al
Background Survivorship for gynecological cancers has increased because of improved screening and treatment. Use of supportive care services after treatment is important to improve patient quality of life. Objective To assess self-reported lower-lim... More »